EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Pharmacokinetics of the antimicrobial agents rifampicin and miconazole released from a loaded central venous catheter



Pharmacokinetics of the antimicrobial agents rifampicin and miconazole released from a loaded central venous catheter



Journal of Hospital Infection 53(2): 129-135, February



The time course of rifampicin and miconazole concentrations after insertion of a polyurethane catheter loaded with these antibiotics were studied. Data from controlled release experiments in vitro were used, and the concentration time courses of the antimicrobials in serum were calculated by pharmacokinetic simulations. Systemic therapy using typical dosages (rifampicin 600 mg/day iv, miconazole 3 X 200 mg/day iv) results in rifampicin concentrations between 54 and 8424 mug/L, and miconazole concentrations between 3567 and 4676 mug/L. After insertion of a polyurethane catheter loaded with these antibiotics, the maximal concentrations after catheter placement were determined as 6 mug/L at 10.7 h for rifampicin, and 13 mug/L at 28.6 h for miconazole. Assuming that the total amount of antibiotics incorporated in the catheter matrix were bioavailable ('worst case'), the resulting maximal concentrations calculated by simulation are 10 mug/L for rifampicin and 65 mug/L for miconazole. Maximal concentrations of rifampicin or miconazole resulting from the insertion of a polyurethane catheter loaded with these antibiotics are, therefore, far below the concentrations resulting from a systemic therapy with the same antimicrobial agents. Even in the worst case, the danger of selecting resistant bacterial strains seems remote because the systemic drug levels are magnitudes of order below subinhibitory concentrations.

(PDF emailed within 0-6 h: $19.90)

Accession: 011137978

Download citation: RISBibTeXText

PMID: 12586573

DOI: 10.1053/jhin.2002.1358



Related references

Antimicrobial central venous catheters in oncology: efficacy of a rifampicin-miconazole-releasing catheter. Anticancer Research 30(4): 1353-1358, 2010

Chlorhexidine-silver sulfadiazine- or rifampicin-miconazole-impregnated venous catheters decrease the risk of catheter-related bloodstream infection similarly. American Journal of Infection Control 44(1): 50-53, 2015

Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. American Journal of Infection Control 31(1): 1-8, February, 2003

Reduced colonization and infection with miconazole-rifampicin modified central venous catheters: a randomized controlled clinical trial. Journal of Antimicrobial ChemoTherapy 54(6): 1109-1115, 2004

A central venous catheter loaded with silver-teicoplanin is able to prevent catheter colonization. Abstracts of the General Meeting of the American Society for Microbiology 94(0): 615, 1994

Central venous catheters coated or impregnated with antimicrobial agents effectively prevent microbial colonisation and catheter-related bloodstream infections. Evidence-Based Medicine 19(2): 56-56, 2014

The use of rifampicin-miconazole-impregnated catheters reduces the incidence of femoral and jugular catheter-related bacteremia. Clinical Infectious Diseases 47(9): 1171-1175, 2008

A new antimicrobial central venous catheter for the prevention of infections. Journal of Hospital Infection 40(SUPPL A): P811, Sept, 1998

In vitro efficacy of a hydrophilic central venous catheter loaded with silver to prevent microbial colonization. Zentralblatt Fuer Bakteriologie. 287(1-2): 157-169,., 1998

In-vitro efficacy of a central venous catheter ('Hydrocath') loaded with teicoplanin to prevent bacterial colonization. Journal of Hospital Infection 22(2): 93-107, 1992

Central venous access devices in treatment of patients with malignant tumors: venous port, central venous catheter and Hickman catheter. Cost-benefit analysis based on a critical review of the literature, personal experiences with 135 port implantations and patient attitude. Der Chirurg; Zeitschrift für Alle Gebiete der Operativen Medizen 66(3): 202-207, 1995

Central venous catheter used for recording intracardiac electrocardiogram. A safe and reliable method for registering atrial potentials using a new device connected to the central venous catheter. British Heart Journal 33(2): 275-276, 1971

Temporary central venous catheter utilization patterns in a large tertiary care center: tracking the "idle central venous catheter". Infection Control and Hospital Epidemiology 33(1): 50-57, 2012